Repairing lungs from within: stem cells harvested from Patients' own airways tested for scarring disease

NCT ID NCT06998706

First seen Jul 20, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This early study tests a new stem cell therapy called REGEND001 for people with interstitial lung disease (ILD), a group of conditions that scar the lungs and make breathing difficult. The treatment uses a patient's own regenerative cells, collected from the airways during a scope procedure, grown in a lab, and then infused back into damaged parts of the lung. The goal is to see if this approach is safe and can improve lung function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a stem cell therapy made from the patient's own lung cells, called REGEND001
What this could lead to
If successful, this approach could offer a new way to repair lung damage in people with interstitial lung disease, potentially improving breathing and quality of life.
What could go wrong
This is an early, small study focused on safety, so it is not yet clear if the treatment works. There may be risks from the bronchoscopic procedure or the cell infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASE (ILD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Ruijin Hospital Hainan Branch, Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Qionghai, Hainan, 571437, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200025, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.